Reply To: Any Info on anti-lingo-1
Hi Harry, Thanks for the info about this possible treatment! These kinds of new info alerts helps all of us!
It appears Biogen has been conducting several Clinical Trials surrounding the use of a new infused drug BIIB033 (anti-LINGO-1 mAb, Interferon beta-1a, Avonex). Three trials are closed with no study results posted. One is still open and in Phase II testing. The drug is not presently proposed to treat CIDP. You can view the trial here:
As of October 2015 the new drug has had mixed results in trials on MS patients with recurring/relapsing forms of MS. There are more reported side affects than other treatments. This may raise a red flag with some folks. However it is a new treatment approach and the trial may cause Biogen to modify the drug for less side affects before it is approved for use by the FDA. You can read about preliminary results posted Oct. 8, 2015, in the New England Journal of Medicine here:
Another monoclonal antibody drug Rituxan has already been approved by the FDA and has proven successful in treating some CIDP patients. You can read my posts about it here: